Vandana Singh
·
July 11, 2025
Benzinga
FDA rejected Capricor's BLA for Deramiocel due to insufficient evidence, requesting more clinical data to support approval for Duchenne therapy.
read more
July 31, 2025
June 16, 2025
Financial Times
May 12, 2025
July 21, 2025
Bloomberg